History of British Intensive Care, C.1950–C.2000
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
VIDEO LARYNGOSCOPY Disdvantages
Debate: Is Video Laryngoscopy Making Direct Laryngoscopy Obsolete? The “Yes” Posi,on Why Video Laryngoscopy Is Winning Over Direct Laryngoscopy D. John Doyle MD PhD Professor of Anesthesiology Cleveland Clinic No Conflicts of Interest h<p://www.medrants.com/100shares.gif Central Arguments • VL is easier to learn than DL • VL is easier to perform than DL • VL is less sGmulang than DL • VL provides be<er visualizaon than DL • VL allows all stakeholders to see the glos • VL equipment is geng cheaper and cheaper • Eventually DL will be only of historical interest - like blind nasal intubaon and digital intubaon VL = videolaryngoscopy DL = direct laryngoscopy But first… some introducGons Prototype of the curved laryngoscope blade developed by Sir Robert Macintosh (1897-1989) and his skilled technician, Mr. Richard Salt. Healy DW, Maes O, Hovord D, Kheterpal S. A systemac review of the role of videolaryngoscopy in successful orotracheal intubaon. BMC Anesthesiol. 2012 Dec 14;12:32. doi: 10.1186/1471-2253-12-32. PubMed PMID: 23241277; PubMed Central PMCID: PMC3562270. Videolaryngoscope Design Issues • Regular or Channeled Videolaryngoscope • Angulaon of the Videolaryngoscope Blade • PosiGoning of Camera on the Videolaryngoscope • Width of the Videolaryngoscope Blade • Oral vs Nasal Intubaon • Malleable vs Rigid Stylet • Angulaon of Malleable Style<ed ETT • Available of a “Bougie Port” • Type of ETT Used (e.g., Pentax AWS) Regular Videolaryngoscopes • GlideScope family • McGrath products • Storz products • AP Advance • CoPilot VL • Truphatek GlideScope GlideScope Direct Ranger Regular Blades Early GlideScope Use (2003) GlideScope Direct Intubaon Trainer (for teaching) GlideScope GlideScope ® Blade Family Family of Products Blade Angle Comparison Homemade Miniature GlideScope Jack Pacey’s Original GlideScope Prototype Ma McGrath Inventor and CEO Ma has a 1st class honours degree in Industrial Design. -
Speakers and Topics
SPEAKERS AND TOPICS SALZBURG WEILL CORNELL SEMINAR ANESTHESIOLOGY AND INTENSIVE CARE Sunday, October 18 – Saturday, October 24, 2020 Schloss Arenberg, Salzburg, Austria Course Director: Hugh C. Hemmings Jr., MD, PhD, FRCA Co-Course Director: Klaus Markstaller, MD Co-Course Director: Kane O. Pryor, MD Co-Course Director: Peter Marhofer, MD SPEAKERS AND TOPICS: Meghann M. Fitzgerald, MD Assistant Professor of Clinical Anesthesiology Weill Cornell Medical College Assistant Attending Anesthesiologist NewYork-Presbyterian Hospital Weill Cornell Medicine Anesthesiology New York, NY USA • Robotic Cardiac Surgery • Blood Management in Cardiac Surgery • TAAA Repair Lukas Kirchmair, MD, PD, DESA, EDRA Department of Anesthesiology and Intensive Care District Hospital Schwaz Schwaz Austria • Polytrauma Management Rudolf Likar, MD, MSc Professor Head, Department of Anesthesiology and Intensive Care General Hospital Klagenfurt Klagenfurt am Woerthersee Austria • Invasive Methods in Cancer Pain • Invasive Methods in Low Back Pain © Open Medical Institute 2020 SPEAKERS AND TOPICS Peter Marhofer, MD Professor of Anesthesia and Intensive Care Medicine Department of Anesthesia and Intensive Care Medicine Medical University of Vienna Vienna Austria • Principles of Regional Anaesthesia I • Principles of Regional Anaesthesia II • Ultrasound in Anaesthesia and Intensive Care Medicine I • Ultrasound in Anaesthesia and Intensive Care Medicine II Rohan Panchamia, MD Assistant Professor of Clinical Anesthesiology Weill Cornell Medical College Assistant Attending -
COVID-19 Pneumonia: Different Respiratory Treatment for Different Phenotypes? L
Intensive Care Medicine EDITORIAL Un-edited accepted proof COVID-19 pneumonia: different respiratory treatment for different phenotypes? L. Gattinoni1, D. Chiumello2, P. Caironi3, M. Busana1, F. Romitti1, L. Brazzi4, L. Camporota5 Affiliations: 1Department of Anesthesiology and Intensive Care, Medical University of GöttinGen 4Department of Anesthesia, Intensive Care and Emergency - 'Città della Salute e della Scienza’ Hospital - Turin 5Department of Adult Critical Care, Guy’s and St Thomas’ NHS Foundation Trust, Health Centre for Human and Applied Physiological Sciences - London Corresponding author: Luciano Gattinoni Department of Anesthesiology and Intensive Care, Medical University of Göttingen, Robert-Koch Straße 40, 37075, Göttingen, Germany Conflict of interests: The authors have no conflict of interest to disclose NOTE: This article is the pre-proof author’s accepted version. The final edited version will appear soon on the website of the journal Intensive Care Medicine with the following DOI number: DOI 10.1007/s00134-020-06033-2 1 Gattinoni L. et al. COVID-19 pneumonia: different respiratory treatment for different phenotypes? (2020) Intensive Care Medicine; DOI: 10.1007/s00134-020-06033-2 Intensive Care Medicine EDITORIAL Un-edited accepted proof The Surviving Sepsis CampaiGn panel (ahead of print, DOI: 10.1007/s00134-020-06022-5) recently recommended that “mechanically ventilated patients with COVID-19 should be managed similarly to other patients with acute respiratory failure in the ICU.” Yet, COVID-19 pneumonia [1], despite falling in most of the circumstances under the Berlin definition of ARDS [2], is a specific disease, whose distinctive features are severe hypoxemia often associated with near normal respiratory system compliance (more than 50% of the 150 patients measured by the authors and further confirmed by several colleagues in Northern Italy). -
Standards for the Diagnosis and Treatment of Patients with COPD
Copyright #ERSJournals Ltd 2004 EurRespir J 2004;23: 932– 946 EuropeanRespiratory Journal DOI: 10.1183/09031936.04.00014304 ISSN0903-1936 Printedin UK –allrights reserved ATS/ ERSTASK FORCE Standardsfor the diagnosisand treatment of patientswith COPD: asummaryof the ATS/ERSposition paper B.R. Celli*, W. MacNee*,andcommittee members Committeemembers: A Agusti, A Anzueto, B Berg, A S Buist, P M A Calverley, N Chavannes, T Dillard, B Fahy, A Fein, J Heffner, S Lareau, P Meek, F Martinez, W McNicholas, J Muris, E Austegard, R Pauwels, S Rennard, A Rossi, N Siafakas, B Tiep, J Vestbo, E Wouters, R ZuWallack *P ulmonaryand Critical C are D ivision, St Elizabeth s’ Medical Center, Tufts U niversity School of Medicine, Boston, Massachusetts, USA # Respiratory Medicine ELE GI, Colt R esearch Lab Wilkie Building, CONTEMedical Schoo l, T eviot Place, Edinburgh, UK CONTENTSNTS Background. ............................ 932 Managementof stab eCOPD:surgery in and for Goals and objectives 933 COPD.. ............................... 938 Participants 933 Surgery in COPD 938 Evidence, methodology and validation 933 Surgery for COPD 938 Concept of a "live",modular document 933 Managementof stab e COPD: s eep. ........... 938 Organisation of the document 933 Managementof stab eCOPD:air-trave . 939 De® nitionof COPD. ...................... 933 Exacerbationof COPD: de® nition, eva uation and Diagnosisof COPD. ...................... 933 treatment ............................... 939 Epidemio ogy,risk factors andnatura history De® nition 939 ofCOPD ............................... 934 Assessment 940 Patho ogyand pathophysio ogyin COPD . ....... 934 Indication for hospitalisation 940 C inica assessment, testingand differentia diagnosisof Indications for admission to specialised or intensive COPD.. ............................... 934 care unit 940 Medicalhistory 935 Treatment of exacerbations 940 Physicalsigns 935 Exacerbationof COPD: inpatient oxygen therapy. -
United States Patent (19) 11 Patent Number: 5,029,579 Trammell (45) Date of Patent: Jul
United States Patent (19) 11 Patent Number: 5,029,579 Trammell (45) Date of Patent: Jul. 9, 1991 54 HYPERBARIC OXYGENATION 4,452,242 6/1984 Bänziger ......................... 128/205.26 APPARATUS AND METHODS 4,467,798 8/1984 Saxon et al. ... ... 128/205.26 4,474,571 10/1984 Lasley ................................... 604/23 75 Inventor: Wallace E. Trammell, Provo, Utah 4,509,513 4/1985 Lasley ....... ... 128/202.12 4,624,656 1 1/1986 Clark et al. ........................... 604/23 73) Assignee: Ballard Medical Products, Midvale, 4,691,.695 9/1987 Birk et al. ............................. 128/38 Utah Appl. No.: 392,169 FOREIGN PATENT DOCUMENTS 21) 317900 12/1919 Fed. Rep. of Germany ... 128/256 22) Filed: Aug. 10, 1989 1 14443 12/1941 United Kingdom ................ 128/248 Related U.S. Application Data OTHER PUBLICATIONS 63 Continuation of Ser. No. 297,351, Jan. 13, 1989, aban TOPOX Literature. doned, which is a continuation of Ser. No. 61,924, Jun. Oxycure Literature. 15, 1987, abandoned, which is a continuation-in-part of B & F Medical Products, Inc. Literature. Ser. No. 865,762, May 22, 1986, abandoned. Primary Examiner-Richard J. Apley (51) Int. Cl. ............................................... A61H 9/00 Assistant Examiner-Linda C. M. Dvorak (52) U.S. Cl. ................................ 128/205.26; 128/30; Attorney, Agent, or Firm-Lynn G. Foster 128/202.12; 128/205.24; 604/23 (58) Field of Search ...................... 128/202. 12, 205.26, 57 ABSTRACT 128/28, 30, 30.2, 38, 40, 402; 600/21; 604/23, A novel hyperbaric oxygenation apparatus, and related 289, 290, 293,304, 305, 308 methods, the apparatus comprising a chamber in the form of a disposable inflatable bag of impervious inex 56 References Cited pensive synthetic resinous material which can be used at U.S. -
Intensive Care Medicine in 10 Years
BOOKS,FILMS,TAPES &SOFTWARE are difficult to read, the editing is inconsis- tory for critical care medicine. The book is initiate a planning process for leaders who tent, and the content that was omitted indi- divided into sections entitled “Setting the recognize the imperative for change and ad- cates that “efforts to bring this work from Stage,” “Diagnostic, Therapeutic, and In- aptation in critical care. Accordingly, I rec- conception to fruition in less than one year” formation Technologies 10 Years From ommend this book to individuals and groups (as stated in the book’s acknowledgments Now,” “How Might Critical Care Medicine engaged in all aspects of critical care man- section) prevented this book from being a Be Organized and Regulated?” “Training,” agement, now and in the future. “gold standard” text. and “The Critical Care Agenda.” Each sec- J Christopher Farmer MD tion consists of a series of essays/chapters Marie E Steiner MD MSc Department of Medicine that discuss various aspects of the topic, and Department of Pediatrics Mayo Clinic all the sections have solid scientific support Divisions of Pulmonary/ Rochester, Minnesota and bibliographies. The individual topics Critical Care and Hematology/ span the entire range of critical-care clinical Oncology/Blood and Marrow The author reports no conflict of interest related practice, administration, quality and safety, Transplantation to the content of this book review. and so forth. The contributors are acknowl- University Children’s Hospital, Fairview edged senior clinical and scientific leaders University of Minnesota Mechanical Ventilation: Physiological in critical care medicine from around the Minneapolis, Minnesota and Clinical Applications, 4th edition. -
Intravenous Immunoglobulin Fails to Improve ARDS in Patients
Prohaska et al. Journal of Intensive Care (2018) 6:11 DOI 10.1186/s40560-018-0278-8 RESEARCH Open Access Intravenous immunoglobulin fails to improve ARDS in patients undergoing ECMO therapy Stefanie Prohaska1, Andrea Schirner1, Albina Bashota1, Andreas Körner1, Gunnar Blumenstock2 and Helene A. Haeberle1* Abstract Background: Acute respiratory distress syndrome (ARDS) is associated with high mortality rates. ARDS patients suffer from severe hypoxemia, and extracorporeal membrane oxygenation (ECMO) therapy may be necessary to ensure oxygenation. ARDS has various etiologies, including trauma, ischemia-reperfusion injury or infections of various origins, and the associated immunological responses may vary. To support the immunological response in this patient collective, we used intravenous IgM immunoglobulin therapy to enhance the likelihood of pulmonary recovery. Methods: ARDS patients admitted to the intensive care unit (ICU) who were placed on ECMO and treated with (IVIG group; n = 29) or without (control group; n = 28) intravenous IgM-enriched immunoglobulins for 3 days in the initial stages of ARDS were analyzed retrospectively. Results: The baseline characteristics did not differ between the groups, although the IVIG group showed a significantly reduced oxygenation index compared to the control group. We found no differences in the length of ICU stay or ventilation parameters. We did not find a significant difference between the groups for the extent of inflammation or for overall survival. Conclusion: We conclude that administration -
Characteristics and Risk Factors for Intensive Care Unit Cardiac Arrest in Critically Ill Patients with COVID-19—A Retrospective Study
Journal of Clinical Medicine Article Characteristics and Risk Factors for Intensive Care Unit Cardiac Arrest in Critically Ill Patients with COVID-19—A Retrospective Study Kevin Roedl 1,* , Gerold Söffker 1, Dominic Wichmann 1 , Olaf Boenisch 1, Geraldine de Heer 1 , Christoph Burdelski 1, Daniel Frings 1, Barbara Sensen 1, Axel Nierhaus 1 , Dirk Westermann 2, Stefan Kluge 1 and Dominik Jarczak 1 1 Department of Intensive Care Medicine, University Medical Centre Hamburg-Eppendorf, 20246 Hamburg, Germany; [email protected] (G.S.); [email protected] (D.W.); [email protected] (O.B.); [email protected] (G.d.H.); [email protected] (C.B.); [email protected] (D.F.); [email protected] (B.S.); [email protected] (A.N.); [email protected] (S.K.); [email protected] (D.J.) 2 Department of Interventional and General Cardiology, University Heart Centre Hamburg, 20246 Hamburg, Germany; [email protected] * Correspondence: [email protected]; Tel.: +49-40-7410-57020 Abstract: The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causing the coron- avirus disease 2019 (COVID-19) led to an ongoing pandemic with a surge of critically ill patients. Very little is known about the occurrence and characteristic of cardiac arrest in critically ill patients Citation: Roedl, K.; Söffker, G.; with COVID-19 treated at the intensive care unit (ICU). The aim was to investigate the incidence Wichmann, D.; Boenisch, O.; de Heer, and outcome of intensive care unit cardiac arrest (ICU-CA) in critically ill patients with COVID-19. G.; Burdelski, C.; Frings, D.; Sensen, This was a retrospective analysis of prospectively recorded data of all consecutive adult patients B.; Nierhaus, A.; Westermann, D.; with COVID-19 admitted (27 February 2020–14 January 2021) at the University Medical Centre et al. -
Effect of Assist Negative Pressure Ventilation by Microprocessor
258 ORIGINAL ARTICLE Thorax: first published as 10.1136/thorax.57.3.258 on 1 March 2002. Downloaded from Effect of assist negative pressure ventilation by microprocessor based iron lung on breathing effort M Gorini, G Villella, R Ginanni, A Augustynen, D Tozzi, A Corrado ............................................................................................................................. Thorax 2002;57:258–262 Background: The lack of patient triggering capability during negative pressure ventilation (NPV) may contribute to poor patient synchrony and induction of upper airway collapse. This study was undertaken to evaluate the performance of a microprocessor based iron lung capable of thermistor trig- gering. Methods: The effects of NPV with thermistor triggering were studied in four normal subjects and six patients with an acute exacerbation of chronic obstructive pulmonary disease (COPD) by measuring: (1) the time delay (TDtr) between the onset of inspiratory airflow and the start of assisted breathing; (2) the pressure-time product of the diaphragm (PTPdi); and (3) non-triggering inspiratory efforts (NonTrEf). In patients the effects of negative extrathoracic end expiratory pressure (NEEP) added to NPV were also evaluated. See end of article for Results: With increasing trigger sensitivity the mean (SE) TDtr ranged from 0.29 (0.02) s to 0.21 authors’ affiliations ....................... (0.01) s (mean difference 0.08 s, 95% CI 0.05 to 0.12) in normal subjects and from 0.30 (0.02) s to 0.21 (0.01) s (mean difference 0.09 s, 95% CI 0.06 to 0.12) in patients with COPD; NonTrEf ranged Correspondence to: from 8.2 (1.8)% to 1.2 (0.1)% of the total breaths in normal subjects and from 11.8 (2.2)% to 2.5 Dr M Gorini, Via Ragazzi (0.4)% in patients with COPD. -
What Are the Respiratory Requirements for the Treatment of COVID-19 Pneumonia?
What are the respiratory requirements for the treatment of COVID-19 pneumonia? Background What happens in the lungs during COVID-19 pneumonia? Patients may require support of their breathing by having ventilatory assistance for a range of reasons, but patients who are seriously affected by COVID-19 will primarily develop pneumonia which may progress to acute respiratory distress syndrome (ARDS) in which there is extreme inflammation with damage and fluid accumulation within the small gas-exchange sacs of the lung (alveoli).1 These patients require specialised ventilation strategies to prevent hypoxia (oxygen depletion of their tissues) which have been well defined2,3, and which are known to deliver optimum therapy4. How is ventilatory assistance conventionally delivered? Since the first positive pressure devices were introduced in the 1950s, it has become conventional to ventilate the lungs, in a wide variety of disease, by delivering positive pressure ventilatory support, either via a tightly-fitting face mask (CPAP), or through a cuffed endo-tracheal tube using positive pressure ventilators (PPV). These devices have become increasingly sophisticated and a whole generation of anaesthetists/intensivists have become expert in their use. However, before this method was introduced there was a long history of using negative pressure ventilation (NPV) by placing the patient’s body within a chamber with their head outside, with a seal at the neck. The lungs were inflated creating a negative pressure in the chamber or tank (the “iron lung”). NPV mimics and enhances natural respiration. The change from NPV to PPV was not a planned decision related to their relative evidence or efficacy, but occurred because of the convenience of not having to manage a patient inside a large tank, and ironically, a shortage of these large and expensive devices during the polio epidemic during the 1950s. -
Position!Statement:!! Tracheostomy! Management!
! ! The!New!Zealand!Speech/language!Therapists’!Association! (NZSTA)! ! ! ! Position!Statement:!! Tracheostomy! Management! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! Copyright!©!2015!The!New!Zealand!Speech;language!Therapists’!Association!! !!!!! ! Disclaimer:!To!the!best!of!The!New!Zealand!Speech;language!Therapists’!Association’s!(‘the!Association’)! knowledge,!this!information!is!valid!at!the!time!of!publication.!The!Association!makes!no!warranty!or! representation!in!relation!to!the!content!or!accuracy!of!the!material!in!this!publication.!The!Association! expressly!disclaims!any!and!all!liability!(including!liability!for!negligence)!in!respect!of!use!of!the! information!provided.!The!Association!recommends!you!seek!independent!professional!advice!prior!to! making!any!decision!involving!matters!outlined!in!this!publication.!! ! ! ! Acknowledgements! ! Working!party! Lucy!Greig!(lead)! Molly!Kallesen! Melissa!Keesing! Anna!Miles! Turid!Peters! Samantha!Scott! Katie!Ward! !! Speech!Pathology!Australia!for!sharing!Speech&Pathology&Australia.&(2013).& Tracheostomy&Management&Clinical&Guideline.&Melbourne:&Speech&Pathology& Australia.&with!members!of!the!New!Zealand!Speech;language!Therapists’! Association.! !! Advisors! Karen!Brewer,!Speech;language!Therapist,!Te!Kupenga!Hauora!Maori,!Faculty!of! Medical!&!Health!Sciences,!The!University!of!Auckland.! ! Erena!Wikaire,!Physiotherapist,!Te!Kupenga!Hauora!Maori,!Faculty!of!Medical!&! Health!Sciences,!The!University!of!Auckland.! ! Reviewers! The!New!Zealand!Speech;language!Therapists’!Association!Executive!Committee! -
MIDDLE EAST JOURNAL of ANESTHESIOLOGY Department of Anesthesiology American University of Beirut Medical Center P.O
MIDDLE EAST JOURNAL OF ANESTHESIOLOGY Department of Anesthesiology American University of Beirut Medical Center P.O. Box 11-0236. Beirut 1107-2020, Lebanon Editorial Executive Board Consultant Editors Editor-In-Chief: Ghassan Kanazi Assem Abdel-Razik (Egypt) Executive Editors Fouad Salim Haddad Bassam Barzangi (Iraq) Maurice A. Baroody Izdiyad Bedran (Jordan) Editors Chakib Ayoub Dhafir Al-Khudhairi (Saudi Arabia) Marie Aouad Sahar Siddik-Sayyid Mohammad Seraj (Saudi Arabia) Managing Editor Mohamad El-Khatib Abdul-Hamid Samarkandi (Saudi Arabia) Founding Editor Bernard Brandstater Mohamad Takrouri (Saudi Arabia) Honorary Editors Nicholas Greene Musa Muallem Bourhan E. Abed (Syria) Anis Baraka (Emeritus Editor-In-Chief) Mohamed Salah Ben Ammar (Tunis) Webmaster Rabi Moukalled Ramiz M. Salem (USA) Secretary Alice Demirdjian Elizabeth A.M. Frost (USA) The Middle East Journal of Anesthesiology is a The Journal is indexed in the Index Medicus and publication of the Department of Anesthesiology of MEDLARS SYSTEM. the American University of Beirut, founded in 1966 E-mail: [email protected] by Dr. Bernard Brandstater who coined its famous Fax: +961 - (0)1-754249 motto: All accepted articles will be subject to a US $ 100.00 “For some must watch, while some must sleep” fee that should be paid prior to publishing the accepted (Hamlet-Act. III, Sc. ii). manuscript and gave it the symbol of the poppy flower (Papaver Please send dues to: somniferum), it being the first cultivated flower in the Middle East which has given unique service to Credit Libanais SAL the suffering humanity for thousands of years. The AG: Gefinor.Ras.Beyrouth Journal’s cover design depicts The Lebanese Cedar Swift: CLIBLBBX Tree, with’s Lebanon unique geographical location between East and West.